PaigePaiges Page

Originally posted in Cystic Fibrosis News From Medical News Today

Adding inhaled dry powder mannitol to standard therapy for cystic fibrosis produced sustained improvement in lung function for up to 52 weeks, according to a new study. Along with the treatment’s efficacy and good safety profile, the convenience and ease of administration of mannitol treatment may improve adherence with therapy in these patients…

Originally posted in Cystic Fibrosis News From Medical News Today

A new study found that the combination of inhaled dry powder mannitol with standard therapy for cystic fibrosis resulted in maintained improvement in lung function for 12 months. In addition to being effective and safe, the easy administration of the treatment might help enhance adherence with treatment in individuals suffering with the condition…

Originally posted in Cystic Fibrosis News From Medical News Today

Adding inhaled dry powder mannitol to standard therapy for cystic fibrosis produced sustained improvement in lung function for up to 52 weeks, according to a new study. Along with the treatment’s efficacy and good safety profile, the convenience and ease of administration of mannitol treatment may improve adherence with therapy in these patients…

Originally posted in Cystic Fibrosis News From Medical News Today

Scientists at Queen’s University Belfast have begun work into improving the lives of thousands of Cystic Fibrosis sufferers thanks to the award of a 1.74 million pound US-Ireland Research and Development Partnership grant…

Mpex Pharmaceuticals, Inc. during the JP Morgan 29th Annual Healthcare Conference, announced that it has initiated its Phase 3 clinical trial program with Aeroquin™ (MP-376) for the treatment of pulmonary infections in patients with cystic fibrosis (CF)…

Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced the top-line results from its second Phase 3 clinical trial, TIGER-2, with denufosol tetrasodium for the treatment of cystic fibrosis (CF)…

A team of Johns Hopkins Children’s Center researchers has discovered that a protein involved in cystic fibrosis (CF) also regulates inflammation and cell death in emphysema and may be responsible for other chronic lung diseases…

Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced that the results from its first Phase 3 clinical trial with denufosol tetrasodium for cystic fibrosis (CF), TIGER-1, have been published in the peer-reviewed publication, American Journal of Respiratory and Critical Care Medicine (AJRCCM)…

Cystic fibrosis (CF) patients with normal to mildly impaired lung function may benefit from a new investigational drug designed to help prevent formation of the sticky mucus that is a hallmark of the disease, according to researchers involved in a phase 3 clinical trial of the drug…

Like an overprotective parent on the first day of school, a targeting factor sometimes needs a little push to let go of its cargo. Scientists at the European Molecular Biology Laboratory (EMBL) in Grenoble, France, have visualised one such hand-over. They were the first to determine the structure of a ribosome-protein complex involved in carrying nascent proteins out of the cell…